Equities

Marker Therapeutics Inc

Marker Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.05
  • Today's Change0.100 / 3.38%
  • Shares traded7.04k
  • 1 Year change+13.86%
  • Beta1.4526
Data delayed at least 15 minutes, as of Nov 22 2024 18:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

  • Revenue in USD (TTM)5.40m
  • Net income in USD-9.63m
  • Incorporated2018
  • Employees8.00
  • Location
    Marker Therapeutics Inc2450 HOLCOMBE BLVDSUITE BCM-A, MS: BCM251HOUSTON 77021United StatesUSA
  • Phone+1 (713) 400-6400
  • Fax+1 (302) 655-5049
  • Websitehttps://markertherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ocean Biomedical Inc0.00-98.59m24.70m9.00---------3.01-3.010.00-2.21---------------------------0.2443--------72.16------
Athira Pharma Inc0.00-109.22m25.34m65.00--0.4426-----2.85-2.850.001.490.00----0.00-80.62-30.73-101.80-32.46------------0.00-------23.04------
Geovax Labs Inc3.09m-24.32m25.48m17.00--2.73--8.24-9.21-9.210.92990.98780.2263----181,774.10-178.10-108.34-276.02-147.24-----787.08-1,842.93----0.00---100.00---85.20------
Equillium Inc45.91m-4.62m25.51m45.00--1.10--0.5555-0.1316-0.13161.290.65431.02--10.461,043,500.00-10.29-46.81-18.30-57.36-----10.05-328.35----0.00--128.97--78.64--7.48--
ABPRO Holdings Inc0.004.29m25.57m--22.791.62----0.13960.13960.001.970.00------2.48--2.53--------------0.00------49,648.60------
Marker Therapeutics Inc5.40m-9.63m26.34m8.00--3.53--4.88-1.08-1.090.60570.8370.355--13.04674,481.30-63.39-53.74-79.76-62.25-----178.54-1,438.71----0.00---5.7674.2728.97------
Lipocine Inc7.92m-4.06m26.74m17.00--1.40--3.38-0.7626-0.76261.483.570.3486--119.56466,054.70-17.85-39.32-19.49-45.87-----51.19-442.26----0.00---670.16---51.99------
DURECT Corp8.59m-17.07m26.77m45.00--22.00--3.12-0.5556-0.55560.28130.03920.21810.74179.05148,172.40-43.33-37.34-156.35-53.4478.8791.83-198.62-139.110.5963-24.300.8958---55.67-10.9621.82---10.98--
Mink Therapeutics Inc0.00-13.78m27.28m31.00---------0.3865-0.38650.00-0.44390.00----0.00-185.76--------------------------19.77------
IGC Pharma Inc1.18m-12.57m27.30m67.00--3.66--23.08-0.1879-0.18790.01710.09630.0880.249913.0717,656.72-93.54-42.46-114.44-46.0756.2120.95-1,062.47-730.000.9779--0.0184--47.64-23.45-12.98--53.72--
Eterna Therapeutics Inc598.00k-44.95m27.34m8.00------45.72-8.31-8.310.1105-8.390.0199--0.609374,750.00-149.86-169.05-222.51-223.0072.91---7,513.88-682.61---5.43-------68.8911.84---58.86--
Hookipa Pharma Inc50.00m-43.37m27.73m151.00--0.3861--0.5545-4.11-4.114.245.960.3653--100.10331,119.20-31.69-41.63-42.40-50.26-----86.74-366.65----0.00--41.2721.41-25.67--14.11--
Longeveron Inc1.85m-27.37m27.74m23.00--1.08--14.98-6.67-6.670.29621.730.0892--7.7880,521.74-86.28-63.15-102.27-75.6873.0633.70-967.49-441.02----0.00---41.98-19.78-17.92--26.80--
SAB Biotherapeutics Inc1.51m-45.57m28.33m57.00--0.7678--18.73-5.84-5.840.17534.000.0368--31.1726,539.12-110.96---142.16-------3,012.26------0.0856---90.63---125.14------
Data as of Nov 22 2024. Currency figures normalised to Marker Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

9.41%Per cent of shares held by top holders
HolderShares% Held
Aisling Capital Management LPas of 30 Sep 2024314.29k3.52%
The Vanguard Group, Inc.as of 30 Sep 2024240.61k2.70%
AR Asset Management, Inc.as of 30 Sep 202473.70k0.83%
Geode Capital Management LLCas of 30 Sep 202471.56k0.80%
Renaissance Technologies LLCas of 30 Sep 202439.75k0.45%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202421.66k0.24%
SSgA Funds Management, Inc.as of 30 Sep 202420.95k0.24%
Dimensional Fund Advisors LPas of 30 Sep 202420.28k0.23%
UBS Securities LLCas of 30 Sep 202419.10k0.21%
BlackRock Fund Advisorsas of 30 Sep 202417.69k0.20%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.